

Treatment of Aggressive Giant Cell Tumor: Intralesional Curettage VS Resection Endoprosthesis

A Systematic Review/Meta Analysis

*Submitted for Partial Fulfillment of Master Degree In
Orthopedic Surgery*

By

Hany Farouk Abd El Adel El Sawy

Bachelor of Medicine and Surgery Ain Shams University

Under Supervision of

Prof. Dr. Mohamed Abdel Rahman Mostafa

Professor of Orthopaedic Surgery

Faculty of Medicine- Ain Shams University

Dr. Sherif Ishak Azmy

Assistant Professor of Orthopaedic Surgery

Faculty of Medicine- Ain Shams University

*Faculty of Medicine
Ain Shams University
2020*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَدَانِكَ لَا نَعْلَمُ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **Allah**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Mohamed Abdel Rahman Mostafa**, Professor of Orthopaedic Surgery, Faculty of Medicine, Ain-Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Sherif Tshak Azmy**, Assistant Professor of Orthopaedic Surgery, Faculty of Medicine, Ain-Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I would like to express my hearty thanks to all **my family** for their support till this work was completed.*

Hany El Sawy

List of Contents

Title	Page No.
List of Tables.....	v
List of Figures	vi
List of Abbreviations.....	8
Introduction	i
Aim of the Work	3
Review of Literature	4
Patients and Methods.....	24
Results.....	28
Discussion	52
Conclusion	59
Recommendations	60
Summary.....	50
References	64
Arabic Summary	--

List of Tables

Table No.	Title	Page No.
Table (1):	Descriptive Data of the included studies (N=18)	28
Table (2):	Comparison between 5 papers regarding complications (secondary osteoarthritis, joint stiffness, fracture after complete healing of the lesion, Postoperative fracture, infection, and failure of internal fixation).....	29
Table (3):	Comparison between 9 papers regarding number of recurrent patients	32
Table (4):	Comparison between 6 papers regarding MSTS score.....	34
Table (5):	Meta-analysis of (Comparison between 7 papers regarding sex)	36
Table (6):	Comparison between 7 papers regarding age	38
Table (7):	Comparison between 6 papers regarding tumor location	39
Table (8):	Comparison between 4 papers regarding follow-up time	40
Table (9):	Meta-analysis: relative risk complications	42
Table (10):	Meta-analysis: risk difference complications	44
Table (11):	Meta-analysis: relative risk recurrence.....	46
Table (12):	Meta-analysis: risk difference recurrence	48
Table (13):	Meta-analysis: continuous measure MSTS score.....	50

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Giant cell tumor.	6
Figure (2):	Macroscopic picture of GCT.....	9
Figure (3):	Giant cell tumor, a storiform arrangement of fibroblasts and macrophages resembles a benign fibrous histiocytoma.....	11
Figure (4):	Typical appearance with large osteoclasts and uniform ovoid mononuclear cells. The vascular lumen contains a mixture of spindle and giant cells	11
Figure (5):	Mechanism of denosumab therapy	20
Figure (6):	Denosumab treatment of GCT.....	22
Figure (7):	Example of trans-arterial embolization of GCT.....	23
Figure (8):	Clinical photo showing the use of high speed burr to extend osseous margins	16
Figure (9):	(a) shows AP X-ray of proximal femur showing Campanacci stage III GCT. (b) shows the excised lesion. (c) shows endoprosthesis replacement on the proximal femur.....	18
Figure (10):	Flow chart of the search for relevant articles.....	26
Figure (11):	Descriptive analysis complications rate in each paper.....	30
Figure (12):	Shows that there is no difference between 5 papers regarding complications.....	31
Figure (13):	Descriptive analysis showing recurrence rate in each paper	33
Figure (14):	Shows that there is no difference between 9 papers regarding recurrence rate.	33
Figure (15):	Descriptive analysis showing MSTS score in each paper.....	35
Figure (16):	Shows that there is highly statistical difference between 6 papers regarding MSTS score.....	35
Figure (17):	Shows that there is no difference between 7 Papers regarding sex.	37

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (18):	Shows that there is no difference between 7 papers regarding age.....	38
Figure (19):	Shows that there is no difference between 6 papers regarding tumor location.	39
Figure (20):	Shows that there the difference between 4 papers regarding follow-up time	40
Figure (21):	Forest plot of Risk Ratio of complications comparing curettage with Resection endoprosthesis.....	43
Figure (22):	Funnel plot of Risk Ratio of complications comparing curettage with Resection endoprosthesis.....	43
Figure (23):	Forest plot of Risk difference of complications comparing curettage with Resection endoprosthesis.....	44
Figure (24):	Funnel plot of Risk difference of complications comparing curettage with Resection endoprosthesis.....	45
Figure (25):	Forest plot of Risk Ratio of recurrence comparing curettage with Resection endoprosthesis.....	46
Figure (26):	Funnel plot of Risk Ratio of recurrence comparing curettage with Resection endoprosthesis.....	47
Figure (27):	Forest plot of Risk difference of recurrence comparing curettage with Resection endoprosthesis.....	48
Figure (28):	Funnel plot of Risk difference of recurrence comparig curettage with Resection endoprosthesis.....	49
Figure (29):	Forest plot of the Standardized Mean Difference of MSTS	50
Figure (30):	Funnel plot of the Standardized Mean Difference of MSTS.....	51

List of Abbreviations

Abb.	Full term
<i>ABC</i>	<i>Aneurysmal Bone Cyst</i>
<i>EC</i>	<i>Extended Curettage</i>
<i>GCT</i>	<i>Giant Cell Tumors</i>
<i>MSTS</i>	<i>Musculoskeletal Tumor Society</i>
<i>RANK k-B</i>	<i>Receptor Activator of Nuclear Factor k-B</i>
<i>RANK-L</i>	<i>Receptor Activator of Nuclear Factor Ligand</i>
<i>SPSS</i>	<i>Statistical Package for Social Science</i>
<i>SR</i>	<i>Segmental Resection</i>

Introduction

Giant cell tumors (GCT) are benign tumors that may have aggressive behavior, it is usually found peri-articular, (Distal femur, proximal tibia, distal radius) with unclear pathogenesis^(1,2,3).

GCT has high recurrence rate as regard of being benign tumor with small percentage of metastasis up to 9% ^(1,2).

GCT is usually presented with pain and limited range of motion due to close proximity to the joints with 12% of patients presented at first by pathological fracture ^(4,5), presentation with a pathological fracture is thought to indicate more aggressive disease with a high risk of local recurrence and metastatic spread ^(5,6,7).

It is usually treated surgically with intralesional curettage being the preferred modality to preserve the anatomy of the bone bearing in mind the young age of affected group ^(8,9,10).

Various studies suggest that wide resection is associated with a decreased risk of local recurrence when compared with intralesional curettage and may increase the recurrence free interval rate from 84% to 100% ^(6,11,12,13).

However, wide resection is associated with higher rates of surgical complications and lead to functional impairment, generally necessitating reconstruction ^(13,14,15,16).

GCT is considered aggressive when possessing the following features: wide zone of transition, cortical thinning, expansile remodeling, or even cortical bone destruction, with an associated soft-tissue mass.

Additionally, it may also contain free-fluid levels due to secondary ABC formation which may occur in up to 14% cases of bone GCT. It may be differentiated from the primary ABC by the presence of an enhancing soft tissue component.

Aim of the Work

To evaluate advantages and disadvantages of the two major modalities in treatment of giant cell tumor (intralesional curettage, resection and replacement with endoprosthesis).

Review of Literature

Epidemiology:

GCT represents around 4-5% of all primary bone tumors and approximately 20% of benign primary bone tumors. the peak incidence is between the ages of 20 to 45.

It's rarely seen in immature individuals and children below 10 years with no race or geographic difference ⁽¹⁷⁾.

GCT is usually solitary lesion with very low incidence of being multicentric.

Pulmonary metastasis is a rare complication that spontaneously regress or remain asymptomatic for years.

Patients with recurrent lesions or primary lesion with aggressive behavior (campanacci III) are at high risk of pulmonary metastasis.

Giant cell tumor usually occurs de novo but also may occur as a rare complication of Paget disease of the bone. The incidence is increased in patients with Paget disease of the bone, in which giant cell tumor is a rare neoplastic complication. Giant cell tumor is a rare complication compared with Paget sarcoma, which has an incidence of sarcomatous change of <5%.

A slight female predominance is noted; approximately 50-57% of cases involve female patients. Vertebral tumors tend to occur in younger patients; 29% of these tumors occur in those aged 10-20 years ⁽¹⁸⁾.

Sites of involvement:

Giant cell tumors typically affect the ends of long bones, especially the distal femur, proximal tibia, distal radius and proximal humerus. Around 5% affect flat bones, especially those of the pelvis. The sacrum is the commonest site in the axial skeleton, while other vertebral bodies are less often involved. Fewer than 5% of cases affect the tubular bones of the hands and feet ⁽¹⁷⁾.




Figure (1): Giant cell tumor.⁽¹⁷⁾

Clinical features of GCT:

The clinical behavior of GCTs ranges from latent, non active tumors to locally aggressive tumors with destruction of the cortex and soft tissue extension. The clinical course of a GCT often is complicated by the tumor's tendency toward local recurrence. Depending on the type of treatment and the local presentation of the tumor, recurrence rates of a primary GCT range from 0% to 65%. Despite their generally benign nature, GCTs are able to seed lung metastases. The frequency of lung metastases ranges from 2% to 5% and the risk for development of lung metastases seems to be associated with local recurrence. In rare occasions, patients can have lung metastases with fatal progression ⁽¹⁹⁾.

The main clinical symptoms are non-specific, local swelling, warmth, and pain radiating independently of weight-bearing. Pathological fracture is the first sign in approximately 15% of cases. The duration of symptoms varies between two to six months and by then, in one-third of cases, the size of the tumor exceeds 50% of the diameter of the affected bone, it has destroyed the cortical bone and reached the subchondral region ⁽²⁰⁾.

Pathogenesis:

Three types of cells are found in benign GCT of bone ^(21, 22). Type I cells look like interstitial fibroblasts, make collagen, and have the capacity to proliferate. This cell is likely the tumor component of GCT. Type I cells share some features of mesenchymal stem cells, they possess features that suggest they could represent an early differentiation into osteoblasts ^(21, 22, 23).